Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Cancers|December 23, 2022
Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer ImmunotherapyShubhmita Bhatnagar, Vishnu Revuri, Manan Shah, et al.
ACS Pharmacology & Translational Science|May 16, 2024
Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium CompoundNazia Nayeem, Sami Sauma, Afruja Ahad, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 6, 2025
A Novel Imidazoquinoline With TLR 7/8, STING, and Inflammasome Activity Demonstrates Antitumor Efficacy in Mouse Melanoma and Neu-Driven Mammary AdenocarcinomaShubhmita Bhatnagar, Vishnu Revuri, Carmen Merali, et al.
Journal of Medicinal Chemistry|November 20, 2014
In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancerMalgorzata Frik, Alberto Martínez, Benelita T Elie, et al.
Apoptosis : an International Journal on Programmed Cell Death|April 3, 2015
Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cellsDannie Bernard, Marinella Gebbia, Swayam Prabha, et al.
Blood|January 30, 2015
AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stressShrivani Sriskanthadevan, Danny V Jeyaraju, Timothy E Chung, et al.
Cancer Cell|June 10, 2015
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid LeukemiaAlicia Cole, Zezhou Wang, Etienne Coyaud, et al.
The Journal of Clinical Investigation|December 4, 2012
Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitorsMahadeo A Sukhai, Swayam Prabha, Rose Hurren, et al.
Pageof 4